<DOC>
	<DOCNO>NCT01649778</DOCNO>
	<brief_summary>This global , multi-centre , long-term , prospective , observational study evaluate treatment pattern clinical outcome patient advance metastatic RCC treat first time pazopanib . The study design enroll approximately 700-1000 patient course enrollment period approximately 18 months.There protocol-mandated visit procedure associate study . Each patient expect participate maximum 30 month premature discontinuation ( i.e. , due death , withdrawal consent , lose follow-up study termination ) .</brief_summary>
	<brief_title>Observational Study Real World Effectiveness Data Safety Patients Receiving Pazopanib With Advanced Metastatic Renal Cell Carcinoma</brief_title>
	<detailed_description>This global , multi-centre , long-term , prospective , observational study evaluate treatment pattern clinical outcome patient advance metastatic RCC treat first time pazopanib . The study design enroll approximately 700-1000 patient course enrollment period approximately 18 month . Sites contact qualified estimate number advanced metastatic RCC patient available enrollment annually . To extent possible , consecutive patient meet inclusion/exclusion criterion enrol . Sites require maintain patient enrolment log eligible patient treatment centre . This log document patient come include exclude study , order ass representativeness study population . The overall number patient site may adjust study meet enrollment goal , need . Eligible patient enrol medical oncologist potentially urologist experience management patient RCC , consistent local practice . There protocol-mandated visit procedure associate study . Each patient expect participate maximum 30 month premature discontinuation ( i.e. , due death , withdrawal consent , lose follow-up study termination ) . Follow-up information collect approximately every 3 month ( window ± 4 week around date suggest data collection allow ) . If patient see regularly schedule visit time , site may contact patient telephone solicit information regard event interest limit loss follow . It anticipate frequency patient assessment image differ accord local standard practice ; therefore quarterly data collection time point intend collect assessment ( date assessment ) since previous visit date .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<criteria>Patients eligible enrolment study must meet following criterion : Age ≥ 18 year enrollment Documented diagnosis advance and/or metastatic clear cell predominantly clear cell RCC Clinical decision make initiate treatment pazopanib prior enrollment study , within 30 day enrollment Willing able provide write informed consent Patients meet follow criterion must enrol study : Patients currently participate interventional clinical trial treatment regimen and/or monitoring dictate protocol Previous exposure investigational license multikinase inhibitor anti VEGF angiogenesis inhibitor advance metastatic disease Life expectancy &lt; 12 week</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>